Background
Introduction
In recent years, the number of travellers to developing countries has increased dramatically, 1 including those with pre-existing medical conditions such as diabetes mellitus. Due to improved awareness and support for travellers with diabetes, their number probably will continue to rise. 2, 3 Travelling to developing countries may complicate an underlying medical condition and may require special considerations and advice. For example, it has been suggested that travellers with diabetes have a higher risk of metabolic dysregulation and symptomatic infectious diseases. [4] [5] [6] Whereas some countries advise all travellers to carry antibiotics, Dutch travel guidelines recommend that only travellers with certain underlying medical conditions, such as diabetes, and travellers to areas with poor health facilities should be prescribed stand-by antibiotics for treatment of diarrhea. 7 British guidelines likewise advise to consider prescribing a course of antibiotics for travellers with certain pre-existing medical conditions. 8 However, data on the association of diabetes mellitus with tropical infections, and on the benefits of preventive and therapeutic measures are lacking. Even evidence for a causal relation between diabetes and domestic infections is limited and inconsistent. 9 The exact number of travellers with diabetes who visit developing countries is not known. In a study published in 1991, 0.4% of 2,445 travellers to the developing world who visited a travel clinic had insulin-dependent diabetes mellitus. 10 Since then, the prevalence of diabetes, both insulin-dependent and non-insulin-dependent, has increased. Annually, about 90 million persons travel to developing countries from North America and Europe, 11 where diabetes prevalence is about 2.8%. 12 Assuming that persons with diabetes travel as frequently as persons without diabetes, an estimated 2.5 million persons with diabetes travel annually from North America and Europe to developing countries. To improve travel advice for this substantial group, we conducted a prospective study with matched controls to see if travellers with diabetes are more susceptible to symptomatic infectious diseases than travellers without diabetes. We also studied the usage of antibiotics for stand-by treatment of diarrhoea among travellers with diabetes.
Methods
Study Population A prospective study with matched controls was performed among travellers who attended the travel clinics of the Public Health Service Amsterdam or the University Medical Centre Leiden between October 2003 and February 2008. All medication-dependent persons 18 years or older with diabetes mellitus were eligible if planning to travel to one or more developing countries together with a non-immune-suppressed travel companion without diabetes, who was within 10 years of their age. Thus, the control group was comparable for travel destination, travel duration, and exposure. Developing countries were defined as those with moderate to high risk on hepatitis A according to the World Health Organization. 13 Travellers with insulin-dependent diabetes (IDD) were defined as patients with diabetes mellitus requiring daily insulin treatment, with or without additional oral anti-diabetics. Travellers with noninsulin-dependent diabetes (NIDD) were defined as patients with diabetes mellitus requiring only oral anti-diabetics.
Survey Methods and Definition of Symptoms A standard questionnaire was used to collect data on socio-demographics and medical history. Items asked for were: sex, age, country of birth, history of diabetes, an immune-disorder, or another medical diagnosis, and use of medication. Participants were asked to fill out a structured diary from the day they visited the travel clinic (up to 4 weeks before departure), until 2 weeks after return from travel. Recorded in the diary were travel itinerary; any episodes of fever, diarrhoea, vomiting, rhinitis, cough, and signs of skin infection; consultation with a doctor; and use of antibiotics or other medication. Fever was defined as a self-measured body temperature of 38.5•C or more. Diarrhoea was defined as loose or watery stools. Rhinitis was defined as nasal discharge or congestion. Cough could be dry or productive. Signs of skin infection included redness or (itching) rash, swelling, tenderness, and/or pus-like drainage. An episode of a symptomatic infection was defined as an aforementioned symptom at one or more consecutive days. The study design was not able to differentiate between non-infectious and infectious causes. Data were collected before departure to gain information about baseline symptoms, and for 2 weeks after return to encompass incubation periods of the most (acute) travel-related infectious diseases. In the Results section, the term 'travel-related' refers to the period of travel itself and the 2 weeks thereafter. The diary also provided for recording non-infectious symptoms and signs, such as signs of metabolic dysregulation. However, regular testing of blood glucose levels was not part of the study protocol, and hypoglycaemia and hyperglycaemia were not defined. Both the questionnaire and the structured diary were specifically developed for this study. According to the Dutch national guidelines on travel advice, only the travellers with medicationdependent diabetes were prescribed ciprofloxacin (500 mg 2 times a day for 3 days), to be used as immediate self-treatment after the first passage of loose or watery stools. 7 Controls were advised to see a doctor in case of diarrhoea with fever, blood in stools, or diarrhoea persisting for 3 days or more. 7 Power-analysis showed that 70 pairs were needed to prove a diarrhoea outcome ratio of 2 or more, with α = 0.05 and power = 80%. This study was approved by a medical ethics committee. All participants gave their informed consent.
Statistical Analysis
For non-independent, non-matched characteristics, McNemar's statistic testing was performed (spss for Windows release 15.0, SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered to be statistically significant.
A random effects Poisson regression model was used to calculate incidence rates and accompanying incidence rate ratios (IRR). Incidence rate was defined as the number of symptom onsets divided by the sum of symptom-free days for all individuals during a specific time period. A random effects logistic regression model was used to calculate median number of symptomatic days and accompanying odds ratios (ORs). Median number of symptomatic days equals an individual's probability to have a symptom per day. It was calculated to compare the disease burden between the travellers with diabetes and their controls. To express results in units per month, numbers per day were multiplied by 30. The random effects model takes into account two levels of correlation: (1) travellers with diabetes and their travel companions had more or less the same exposure, and thus are not independent; (2) for incidences, there may be repeated episodes of a symptom within an individual; for numbers of symptomatic days, presence of symptoms over the days within an individual are correlated. IDD and NIDD were analyzed separately. For estimation of the parameters, a Bayesian approach was used, starting with non-informative priors. Posterior distributions were obtained by Markov Chain Monte Carlo methods, using the WinBUGS program. 14, 15 Three chains were generated, based on different sets of baseline values. Parameter estimates are the medians of the posterior distributions. The range from the 2.5% to the 97.5% quantile is used to quantify the uncertainty in the parameter estimates. This range can be interpreted as a 95% confidence interval and will be referred to as such. If 1 is not included in the 95% confidence interval of a ratio, the ratio can be considered statistically significant (p < 0.05).
Results
During the study period, 210 persons with diabetes planning to travel with a non-immunesuppressed companion without diabetes were eligible for inclusion: 93 IDD and 117 NIDD. Of these 210 eligible pairs, 58 (28%) did not participate, citing lack of time (34%), lack of interest (57%), or reasons unspecified (9%). The remaining participants all provided a completed diary.
Characteristics of the Study Sample
The study sample comprised 70 IDD and their 70 controls, plus 82 NIDD and their 82 controls. Of these 152 pairs, 137 (90%) were included at the Public Health Service Amsterdam, and 15 (10%) at the University Medical Centre Leiden. Table 1 shows the characteristics per type of diabetes. Sixty-four IDD (91%) and 70 NIDD pairs (85%) matched for country of birth; only 8 IDD (11%) and 12 NIDD pairs (15%) matched for gender (data not shown). The IDD more often had cardiovascular disease and dyslipidemia than their controls (p < 0.05). There was no difference in the use of gastric acid inhibitors. The NIDD more often had non-ischemic cardiovascular disease and dyslipidemia than their controls (p < 0.05). Their use of gastric acid inhibitors seemed more frequent, but not significant. Table 2 shows the travel-related symptoms by prevalence, incidence rate, mean duration among symptomatics, and median number of symptomatic days per symptom for IDD and their travel companions. The figure in Table 2 shows the accompanying IRRs and ORs on a logarithmic scale. Likewise, Table 3 shows the results for NIDD and their controls.
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IDD and Controls
The prevalence of travel-related diarrhoea was 44% among IDD and 41% among controls. The incidence rate of travel-related diarrhoea was 0.99 per person-month versus 0.74; the IRR showed no significant difference. The median number of days with diarrhoea was 1.54 per month among IDD, comparable to controls. Diarrhoea outcome measures before travel showed no significant differences between IDD and controls (p > 0.05) (data not shown). Diarrhoea incidence rate and median number of symptomatic days were higher during travel than before travel, for both IDD and their controls (p < 0.05) (data not shown).
The IDD and controls did not significantly differ in travel-related incidence rates and median number of symptomatic days for vomiting, fever, cough, rhinitis, and signs of skin infection. They also did not differ pre-travel, except that the median number of days with cough was lower among IDD (p < 0.05) (data not shown). Travel-related and pre-travel outcome measures did not differ significantly, except that cough among IDD increased after departure in incidence rate and median number of symptomatic days (p < 0.05), although confidence intervals approximated 1 (data not shown).
NIDD and Controls
The prevalence of travel-related diarrhoea was 39% among NIDD and 43% among controls. The incidence rate was 0.75 per person-month versus 0.70; the IRR showed no significant difference. The median number of days with diarrhoea was 1.57 per month among NIDD, comparable to controls. Pre-travel diarrhoea incidence rate and median number of symptomatic days were higher for NIDD than controls (p < 0.05) (data not shown). Diarrhoea incidence rate and median number of symptomatic days were higher during travel than before travel for both NIDD and controls (p < 0.05) (data not shown).
Travel-related incidence rates and median number of symptomatic days for vomiting, fever, cough, and rhinitis were comparable between both groups. The travel-related incidence rate and median number of days for signs of skin infection were higher among NIDD than among controls. However, these measures also differed before travel (data not shown) and showed no significant increase after departure (data not shown). Before travel, incidence rate and median number of symptomatic days for vomiting were higher for NIDD than controls (p < 0.05) (data not shown).
Travel-related and pre-travel outcome measures did not differ significantly, except that rhinitis and vomiting among controls increased after departure in both incidence rate and median number of symptomatic days (p < 0.05) (data not shown).
Treatment and Doctor Consultation Only 6 out of 31 IDD with diarrhoea (19%) and 5 out of 32 NIDD (16%) used the stand-by antibiotics. Effect on the duration of diarrhoea was unclear due to small numbers. Of IDD, 7 (23%) used loperamide or activated carbon, and 3 (10%) used oral rehydration solution, versus 10 (34%) and 1 (3%) of 29 controls with diarrhoea, respectively (not statistically different). Of NIDD, 9 (28%) used loperamide or activated carbon, and 1 (3%) used oral rehydration solution, versus 12 (34%) and 1 (3%) of 35 controls with diarrhoea, respectively (not statistically different).
As to the use of other medication (antibiotics, antipyretics, and anti-inflammatory drugs) and doctor consultations, both IDD and NIDD were comparable to their controls.
Discussion
This is the first prospective study evaluating whether medication-dependent travellers with diabetes to developing countries are at increased risk for developing symptomatic infectious diseases. Although we hypothesized that they would have symptoms more often and longer than non-immune-suppressed travellers without diabetes, no differences in travel-related diarrhoea, vomiting, fever, cough, or rhinitis were found. The NIDD had signs of skin infection more often than controls, unrelated to travel. A higher incidence rate and burden of non-travel-related signs of skin infection among persons with diabetes have been reported before, irrespective of insulin use. 9,16 Why we found increased risk for skin infection only among NIDD and not IDD may reflect differences in age, exposure, or unknown co-morbidity, such as pre-existing skin disease, carriage of Staphylococcus aureus, peripheral neuropathy, or microvascular disease. 9, 17 Because bacterial skin infection can be life-threatening, especially for people with diabetes, stand-by antibiotics for this may be useful for areas where the availability of proper treatment is poor. This needs further investigation. Before travel, disease burden of cough seemed to be lower among IDD than controls. This coincided with a higher prevalence of asthma or chronic obstructive pulmonary disease among the controls, although the difference was not statistically significant (p > 0.05). Before travel, outcome measures for diarrhoea and vomiting were higher among NIDD than controls. The increased diarrhoea might be explained by medication, as the oral anti-diabetic metformin is known for such gastrointestinal side effects. 18 Also, diarrhoea has been associated with metabolic dysregulation. A retrospective population-based survey linked poorer levels of selfreported glycaemic control with a higher prevalence rate of non-travel-related diarrhea. 19 Our study design had distinctive strengths. Structurally specified data were obtained prospectively and on a daily basis. Data collection started before departure (median 15 days) to gain insight into pre-existing symptoms. It continued until 2 weeks after return from travel to encompass incubation periods of the most (acute) travel-related infectious diseases. With a travel companion serving as a matched control, situational specifics for travellers with diabetes and controls were comparable, which minimized any differences in exposure to infectious agents between the two groups. Both groups also matched for age and country of birth, but not for gender: travellers with diabetes were more often male. Yet, prospective studies on travel-related infectious diseases found no association of symptoms of infectious diseases and gender. 20, 21 Theoretically, if one of the sexes document their symptoms better than the other, differences between travellers with diabetes and their travel companions may have been underestimated or overestimated. Groups did not match for cardiovascular disease and dyslipidemia. However, we are not aware of any association of travel-related infection and cardiovascular disease or dyslipidemia. The prevalence of diabetes among visitors of our clinic was 3.1%, comparable with the general population. 12 Also, age and male-female ratio of our subjects with diabetes were comparable with the general diabetic population. Participants' travel destinations were equally distributed across the four regions. Their median travel duration of 20 days corresponded well with the median travel duration of the average traveler. 22, 23 Thus, the study sample can be considered representative, and results can reasonably be applied to the average traveller with diabetes to a developing country. This study also had some limitations. Sample size may not have been large enough to detect small differences. Secondly, some of the symptomatic illnesses could have been due to a noninfectious cause. Although the study design with a travel companion serving as a matched control minimized differences in exposure to environmental and infectious agents between the two groups, this may have overestimated the (absolute) rate of infection in all groups. Thirdly, although the diary provided information on symptom duration, it did not distinguish mild symptomatology from severe. For example, travellers with diabetes could have had more bowel movements or more water loss. Finally, travellers with diabetes and controls differed in counseling and prescription; some travellers with diabetes did use the stand-by antibiotics. Therefore, the data may be skewed toward seeing less differences in outcome measures between both groups. Regular testing of blood glucose levels during travel was not part of the study protocol. Yet, three IDD (4.3%) and two NIDD (2.4%) reported dysregulation of blood glucose levels during travel. Two IDD reported hypoglycaemia coinciding with non-febrile diarrhoea, for which one took stand-by antibiotics. Both NIDD only reported hyperglycaemia; in one traveller this coincided with nonfebrile diarrhoea, for which no stand-by antibiotics were taken. There is only one previous publication on travel-related dysregulation, which suggested that travel to the tropics is a risk factor for metabolic dysregulation. 4 Yet, data were collected retrospectively, by telephone interviewing, and the study sample comprised only 19 subjects, all IDD. With improvements in the quality and use of insulin preparations and treatment schedules, 5, 24, 25 travellers with diabetes might now be more aware and compliant with anti-diabetic therapy. This needs further investigation. Our findings represent persons with diabetes who sought pre-travel health advice. They may have had a more than average health awareness, particularly having received travel advice and knowing the objectives of the study. As to usage of stand-by antibiotics, its importance was emphasized by an experienced travel health expert, and by means of information leaflets. Nevertheless, 83% of the patients with diarrhoea did not use this treatment, even in the case of metabolic dysregulation. Of 152 stand-by antibiotic courses provided, 141 (92.8%) were not used. Moreover, NIDD only reported hyperglycemias. Indeed, hypoglycaemia is uncommon when using only oral anti-diabetics. 26 Thus, routine prescription of stand-by antibiotics for uncomplicated diarrhoea is probably not more useful than for healthy travellers. For IDD, monitoring blood glucose more frequently, and adjusting insulin dosage and diet accordingly, are probably more helpful in minimizing metabolic dysregulation. Stand-by antibiotics may be useful for diabetic travellers to areas where health facilities are lacking in case of more severe illness, for example three or more unformed stools per 24 hours with accompanying symptoms such as fever, or blood in stools. The merits of this definition could not be assessed in this study.
In conclusion, this study showed that medication-dependent travellers with diabetes to developing countries do not have travel-related symptoms of diarrhoea, vomiting, fever, cough, rhinitis, and signs of skin infection more often or longer than travellers without diabetes. The incidence of metabolic dysregulation among travellers with diabetes should be assessed in more detail. Our findings indicate that routine prescription of stand-by antibiotics for travellers with diabetes to areas with good health facilities is probably not more useful than for healthy travellers.
